南方财经7月16日电,复旦张江在2025年7月9日和10日的调研中表示,公司ADC平台研发进展顺利。治疗三阴乳腺癌、膀胱癌、胃癌等多种肿瘤的抗Trop2抗体偶联药物已在ASCO官网发表了I期临床研究数据结果,针对TNBC适应症的III期临床研究正在进行中。此外,基于全新linker-drug平台BB05,多个ADC项目如抗DLL3抗体偶联药物、抗Her2抗体偶联药物等也取得了积极成果,其中抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.